Article
Combined immunochemotherapy in selected patients with metastatic renal cell carcinoma: HLA class II genotype can help to predict response to therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Mar 2011
Bierer Stefan, Hoffmeister Ina, Gerss Joachim, Herrmann Edwin, Wülfing Christian, Sibrowski Walter, Hertle Lothar, Kelsch Reinhard
Abstract excerpt
A number of new agents have been approved for systemic therapy of metastatic renal cell carcinoma (mRCC) recently. Thereby, prognostic factors may aid in predicting the effectiveness of various treatment modalities in individual cases. Aim of this study was to determine the value of human leukocyte antigen (HLA) class II characteristics in predicting response of mRCC to combined immunochemotherapy (ICT). A...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.